INTRODUCTION
============

Lipids are central molecules in cell biology. They are the building blocks for membranes, which give structure to eukaryotic cells. Yet the diversity of lipid species is paramount, too, since different lipids convey different physical and thus functional properties on membranes. Membrane fluidity, curvature, peripheral protein recruitment, as well as membrane protein regulation are all controlled by the different lipids that form a membrane ([@B53]). It follows that understanding the intricate molecular choreography of cells requires a detailed understanding of the dynamics and disposition of lipids in addition to the more familiar proteins.

Lipids present unique challenges for developing tools to study them. When compared with proteins (the biomolecules most familiar to a typical cell biologist), there are some parallels: Like proteins, antibodies have been developed to probe lipids, forming the basis of approaches akin to Western blot and immunofluorescence. The chemistry of lipid extraction for blotting is very different, and blotting is now largely being superseded by mass spectrometry approaches ([@B54]). Immunofluorescence of lipids is possible, though it is even more tricky and artifact prone than it is for proteins, since lipids fix poorly and membranes must be disrupted to allow access of antibodies to internal lipids. Alternatively, akin to fluorescent protein tagging, fluorophore labeled lipids have been developed and successfully used to probe lipid distribution and traffic. However, a huge caveat to these approaches is that a significant region of the hydrophobic tail or head group is replaced with the fluor. Therefore, there is greater potential for occluding crucial interactions that drive lipid localization or function. In addition, selective delivery of the lipids to the correct cellular locale can be difficult or impossible, and the lipid may be metabolized into other species that are indistinguishable by fluorescence. Therefore, in this Perspective, we focus on the genetically encoded lipid biosensors, derived from specific lipid-binding domains. These possess the advantages of being compatible with living cells, detecting the endogenous lipids, and (when used carefully) having limited effects on lipid metabolism and distribution. For a wider primer on the full range of approaches described above, we direct the reader to an excellent recent review ([@B48])

CURRENT LIPID BIOSENSORS
========================

The association of proteins with lipids is usually mediated by specialized lipid-binding domains ([@B48]; [@B27]). In addition, a number of bacterial effectors and toxins can target host cell membranes by binding to lipids ([@B48]; [@B75]). These isolated domains, effectors, and toxins form the basis of genetically encoded lipid biosensors. They can be made as recombinant proteins and used for staining or blotting approaches. More commonly, they are expressed as fusions with fluorescent proteins to allow direct visualization of the lipids in cytosolic membrane leaflets of living cells. [Table 1](#T1){ref-type="table"} lists lipid-binding domains that can be used for this purpose.

###### 

Commonly used genetically encoded biosensors and the criteria used to assess their interpretation; see the text for a discussion. Continued

  --
  --

^a^The accuracy of this probe is disputed.

Each biosensor has a number of potential caveats and pitfalls that the user should be aware of. We think of three crucial criteria that should be considered when determining the validity of a probe: Is the probe specific for the target lipid? Is the biosensor\'s localization dependent on that lipid? And, if it is dependent, is the lipid alone sufficient to localize the biosensor? A previous review ([@B27]) has explained each of these criteria in detail. [Table 1](#T1){ref-type="table"} describes whether these criteria are met, and it is intended as a guide in selecting the most appropriate biosensors. Many are available through the plasmid sharing resource Addgene ([www.addgene.org](http://www.addgene.org)).

THINGS TO THINK ABOUT WHEN USING LIPID BIOSENSORS
=================================================

Selectivity of the biosensor
----------------------------

A quick perusal of [Table 1](#T1){ref-type="table"} reveals that relatively few probes meet all of our prescribed criteria for truly selective, unbiased lipid biosensors. However, this does not mean that they cannot be used to gather useful information about lipid localization and dynamics. However, care must be taken with the interpretation of results. This is illustrated well by the number of probes that recognize PI4P; most have additional binding sites for other ligands that bias lipid detection in compartments that also contain this ligand. They can be useful in reporting changes in PI4P levels in these individual compartments but are often blind to changes in other regions of the cell.

Sometimes it can be assumed that alternative interactions with other lipids will have minimal effects; for example, as [Table 1](#T1){ref-type="table"} shows, the Tubby c-terminal domain binds to PI(3,4,5)P~3~ and PI(3,4)P~2~ in addition to PI(4,5)P~2~. Nevertheless, even after stimulation, these other lipids are present at \<5% of PI(4,5)P~2~ ([@B67]) and are therefore assumed not to alter localization of the biosensor.

A long-time controversy has been whether the soluble headgroup, which are usually present in the cytosol, competes with binding to the lipid. The biggest example has been competition of PH-PLCδ1 from membrane PI(4,5)P~2~ by the lipid\'s hydrolysis product, IP~3~. The short answer is that both reductions in the lipid as well as increases in IP~3~ that occur after phospholipase C activation can lead to dissociation of the biosensor from the membrane, and it is not possible to prescribe a priori the contribution of each ([@B80]). Therefore, we urge caution when interpreting loss of localization of this biosensor after phospholipase C activation. This is a perfect example of when the Tubby c-terminal domain and its variants, which do not bind IP~3~, are a better probe ([@B56]).

Inhibitory effects of the biosensor
-----------------------------------

Perhaps the greatest fear associated with the use of lipid biosensors is that they can sequester their target lipid and hence disrupt physiologic interactions with effector proteins. For this reason, articles such as this usually advise the reader to use the lowest possible expression levels of biosensor possible (e.g., [@B75]). This is good advice, but it reminds us of Rick Sanchez, the fictitious mad scientist from the sci-fi cartoon "Rick and Morty," who once quipped: "Ok... well, sometimes science is more art than science... A lot of people don\'t get that." Rather than leave the reader to the art of determining appropriate expression levels, we will sketch out some slightly more quantitative considerations.

Most biosensors in [Table 1](#T1){ref-type="table"} bind with a 1:1 stoichiometry and with high affinity. In this case, it is permissible to estimate the concentration of lipids as if they were dissolved in the three-dimensional volume of the cell (though this does not apply to tandem arrays of lipid binding domains with more than one binding site, which are much more sensitive to the high local concentration of lipid on the two-­dimensional membrane surface). Estimates of this three-dimensional-equivalent concentration in a typical mammalian cell vary from ∼1 mM for bulk lipids like phosphatidylserine (PS) or phosphatidylcholine (PC), down to ∼10 µM for PI(4,5)P~2~ or 100 nM for PI(3,4,5)P~3~ ([@B67]; [@B52]). The fraction of total expressed biosensor that binds to lipid (*f*~biosnesor~) is related to the binding site\'s dissociation constant (*K*~D~) by the following relationship:

From this, we can see that a biosensor must have a *K*~D~ similar to or substantially lower than that of the effective lipid concentration for appreciable localization when expressed in cells. This is either known to be the case or inferred from the localization of the biosensors listed in [Table 1](#T1){ref-type="table"}.

Given these dissociation constants, it follows that if the concentration of biosensor in cells approaches or exceeds the concentration of lipid, a significant fraction of the lipid will be sequestered. This may begin to displace endogenous proteins and interactions, causing inhibitory effects. How likely is this? Typical yields for protein expression in mammalian systems reveal an upper limit of ∼100 µM for overexpressed protein in the cytosol (estimated as 1 mg/ml culture volume, 50-kDa protein, 2.5 × 10^6^ cells/ml, 15-pl cell volume), whereas expression of lipid biosensors in cells has been found in the range of 1--10 µM ([@B80]). So, sequestering of significant fractions is unlikely for bulk lipids like PS or cholesterol, whereas it is a real concern with less abundant lipids, that is, the phosphoinositides. Indeed, dominant negative effects have been observed with the PI(4,5)P~2~ biosensor PH-PLCδ1 ([@B74]; [@B31]). However, such dominant negative effects have been rare, and it appears that cells compensate by synthesizing more PI(4,5)P~2~ in response to biosensor expression ([@B72]), likely keeping the free lipid concentration constant. This may explain how it is possible to use the PI(3,4,5)P~3~ biosensors listed in [Table 1](#T1){ref-type="table"}, since these have *K*~D~ ≈ \[PI(3,4,5)P~3~\] ≈ 100 nM, and likely sequester the majority of synthesized lipid. By contrast, we estimate that HeLa cells contain ∼500 nM of endogenous effector protein from published proteomic data ([@B29]).

Simple sequestering of the lipid is not the only potential concern when using biosensors. Several of the lipid binding domains listed in [Table 1](#T1){ref-type="table"} also have protein ligands, which may be present at much lower effective cytosolic concentrations ([@B29]), and therefore be much more susceptible to sequestration. Furthermore, the accumulation of high densities of lipid binding proteins on membranes can have other deleterious effects due to protein crowding, such as membrane deformation ([@B64]). For this reason, it is still always advisable to keep biosensor expression levels as low as practicable for imaging purposes. However, with modern instruments, ∼1 µM is adequate for high-quality images and should not cause deleterious effects for most lipids.

The treachery of images
-----------------------

Belgian surrealist painter René Magritte famously produced a painting of a pipe with an accompanying legend, "Ceci n\'est pas une pipe" ("This is not a pipe"); this illustrated the fact that the painting is merely a representation of an object, distinct from the real thing. Similarly, it is important to bear in mind that the biosensor is not the same as the lipid it is being used to detect. First, biosensors are in equilibrium with the free pool of lipid and will not interact with lipids bound to effector proteins; similarly, effector proteins cannot bind to biosensor-bound lipids. Given that lipid--biosensor complexes can diffuse several microns in the plane of the membrane ([@B25]), biosensors often cannot detect local enrichment of lipids associated with specific protein complexes, unless the biosensor has a low affinity (and hence rapid dissociation rate) or is specifically targeted to that protein complex via a secondary, low-affinity interaction ([@B73]; [@B28]). That said, most complexes of biosensor or effector protein last only a few seconds---so effector-bound, free, and biosensor-bound lipids rapidly equilibrate with each other.

A second key point is that the biosensor is expressed in the cell independently of the presence of its lipid target; the lipid only influences the localization of the biosensor. Therefore, changes in local concentrations of the lipid cause changes in biosensor localization and not overall changes in its expression level or total fluorescence---this key point is occasionally lost in the literature. For the purposes of quantification, it is necessary to keep this concept of localization and measure fluorescence intensity changes relative to the membrane compartment of interest. This can be accomplished in a number of ways; for example, by generating a mask corresponding to specific organelles via expression of secondary markers and measuring intensity in the masked region relative to the rest of the cell, by selectively imaging the plasma membrane via total internal reflection fluorescence microscopy (TIRFM), or by using resonant energy transfer approaches to detect biosensor accumulated at a specific membrane. Several recent articles have described these approaches in detail ([@B27]; [@B75])

We illustrate the need to be mindful when interpreting localization in [Figure 1](#F1){ref-type="fig"}. The figure shows cells expressing a high-affinity PI4P probe, GFP-P4C, before and after a treatment. We visualize an increase in fluorescence on endosomes posttreatment. This observation could be the result of an increase in PI4P on endosomes or a loss of lipid where the probe was initially bound. The change in [Figure 1](#F1){ref-type="fig"} is actually the result of a PI4P phosphatase being recruited to the plasma membrane, leading to degradation of this lipid and loss of P4C localization there. The P4C relocalized to organelles where PI4P was still present, which is observed as an increase in fluorescence at these membranes.

![Ceci n\'est pas une PIP ("This is not a PIP"). This COS-7 cell is expressing GFP-P4C, a PI4P biosensor. The images show the cell before and after a treatment that induces relocalization of the probe. What do you suppose this treatment was? Read the text for the answer.](mbc-29-1526-g001){#F1}

Go low or go high?
------------------

The most striking fluorescence images of cell structure are produced when there is the highest contrast between the cellular structure and the rest of the cell. For lipid biosensors, this will correspond to a high fraction of biosensor bound to membrane, that is, a high-affinity (or low *K*~D~). High-affinity probes can be made by tandem dimers or trimers of lower-affinity domains, with a resulting multiplicative increase in affinity---though this approach has pros and cons. For example, a tandem dimer of the P4M PI4P probe allows enhanced detection of PM and endosomal pools of PI4P; conversely, the increased affinity can lead to greater sequestration of lipid and even distort organelles at higher expression levels ([@B24]).

High-affinity probes come with another setback: if the majority of biosensor is already bound to lipid, then it will not detect increases in that lipid. [Figure 2](#F2){ref-type="fig"} shows a single (P4Mx1) or tandem (P4Mx2) PI4P probe after the recruitment of a PI(4,5)P~2~ phosphatase, which elevates PI4P in the plasma membrane. We can observe an increase of the P4Mx1 probe at the membrane after the recruitment of the phosphatase, while little translocation of P4Mx2 is observed---which could be misinterpreted as a lack of lipid production. Indeed, a little trumpeted fact about the popular PI(4,5)P~2~ probe, PH-PLCδ1, is that it is poorly able to detect increases in plasma membrane PI(4,5)P~2~ ([@B68])

![Go high or go low (affinity). These HeLa cells are expressing either a monomeric (top) or a dimeric (bottom) version of GFP-P4M, a PI4P biosensor. The images show the cells before and after activation of a 5-phosphatase that increases PI4P in the plasma membrane. The lower affinity biosensor is able to detect small changes in PI4P synthesis and relocalize to the PM (note how the cytoplasm looks dimmer in the "after" image), whereas the higher-affinity probe is already saturated at the plasma membrane.](mbc-29-1526-g002){#F2}

Lower-affinity probes produce much less striking images---but can be much more informative regarding changes in lipid concentrations. They are also much less prone to the inhibitory effects discussed above, and their shorter lifetime in complex with lipids can allow them to report on local lipid accumulations missed by higher-affinity domains ([@B87]; [@B73]). However, the low affinity can also make it hard to quantify decreases in lipid concentration in a particular membrane, for example, the drop in PI(4,5)P~2~ levels after PLC activation. For these reasons, in our lab we often employ both low- and high-affinity biosensors, when they are available, for a given lipid species.

CONCLUSION
==========

The aim of this Perspective was to provide a current (perhaps fleetingly so) overview of the available genetically encoded lipid biosensors. As we have discussed, these tools may have some limitations, but when controlled, quantified, and interpreted properly, these probes provide invaluable information regarding lipid dynamics. There are a large number of probes available for a wide selection of lipids. However, some lipids still lack high-quality biosensors or any biosensor at all (e.g., PI). The area of biosensor development is a quickly moving field with continuous advancements; new lipid-binding domains are continually being recognized or modified to improve their efficacy. Therefore, we expect the current list ([Table 1](#T1){ref-type="table"}) to become rapidly outdated. However, the principles and pitfalls we have outlined will be as applicable for future generations of lipid biosensors as they are for the current suite.
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Chol

:   cholesterol

DAG

:   diacylglycerol

EE

:   early endosome

ER

:   endoplasmic reticulum

IP ~3~

:   inositol 1,4,5-trisphosphate

LE

:   late endosome

NE

:   nuclear envelope

PA

:   phosphatidic acid

PI3P

:   phosphatidylinositol 3-phosphate

PI4P

:   phosphatidylinositol 4-phosphate

PI5P

:   phosphatidylinositol 5-phosphate

PI(3,4)P ~2~

:   phosphatidylinositol 3,4-bisphosphate

PI(3,5)P ~2~

:   phosphatidylinositol 3,5-bisphosphate

PI(4,5)P ~2~

:   phosphatidylinositol 4,5-bisphosphate

PI(3,4,5)P ~3~

:   phosphatidylinositol 3,4,5-­trisphosphate

PM

:   plasma membrane

PS

:   phosphatidylserine

SM

:   sphingomyelin.
